MEK
Mitogen-activated protein kinase kinase (MEK), primarily represented by MEK1 (MAP2K1) and MEK2 (MAP2K2), is a dual-specificity protein kinase that phosphorylates and activates extracellular signal-regulated kinases ERK1 and ERK2, thereby functioning as a central signaling relay within the MAPK/ERK cascade[1][2]. MEK operates downstream of RAS and RAF kinases and transduces extracellular and intracellular signals into programs controlling cell proliferation, differentiation, survival, transcriptional regulation, and development[2][3][4]. Mechanistically, RAF-mediated activation of MEK enables phosphorylation of ERK proteins at the conserved Thr-Glu-Tyr motif, leading to signal propagation through the canonical MAPK pathway[2][5]. Aberrant activation of MEK signaling has been associated with multiple human diseases, including melanoma, lung cancer, ovarian cancer, leukemia, lymphoma, and developmental disorders linked to dysregulated RAS/MAPK signaling[2][6][7]. Compared with other MAP2K family members that regulate the p38 or JNK pathways, MEK1 and MEK2 function specifically within the ERK signaling branch, providing pathway selectivity and making them key experimental targets for dissecting MAPK-dependent biological responses[1]. For experimental applications, pharmacological MEK inhibitors including trametinib, selumetinib, cobimetinib, binimetinib, mirdametinib, and avutometinib are widely used to suppress ERK activation and investigate MEK-dependent signaling mechanisms in cancer and developmental biology models[2].
-
MEK Related Products (152)
Related Products (152)
-
Antibodies (2)
-
MEK1 P124L Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70745MEK1 is the MAP/ERK kinase. The MEK1 kinase directly phosphorylates ERK2, after the activation loop of MEK1 is itself phosphorylated by Raf. MEK1 P124L is a mutant of MEK1. MEK1 P124L Recombinant Human Active Protein Kinase is a recombinant MEK1 P124L protein that can be used to study MEK1 P124L-related functions.
-
Anti-MP1 Antibody
0 ImagesCat. No.: HY-P992268
-
Cobimetinib (Standard)
0 ImagesSynonyms: GDC-0973 (Standard); XL518 (Standard)Cobimetinib (Standard) is the analytical standard of Cobimetinib. This product is intended for research and analytical applications. Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral MEK1 inhibitor with an IC50 of 4.2 nM for MEK1.
-
Selumetinib (Standard)
0 ImagesSynonyms: AZD6244 (Standard); ARRY-142886 (Standard)Selumetinib (Standard) is the analytical standard of Selumetinib. This product is intended for research and analytical applications. Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.
-
Simetryn (Standard)
0 ImagesSimetryn (Standard) is the analytical standard of Simetryn (HY-B1853). This product is intended for research and analytical applications. Simetryn is a triazine herbicide that exerts teratogenicity. Simetryn inhibits photosynthesis by blocking electron transfer in the chloroplast photosystem II and activates the MEK/Erk signaling pathway. Simetryn triggers vascular and developmental abnormalities in zebrafish and tadpoles, suppresses proliferation, enhances apoptosis, and induces malformations. Simetryn serves as a tool to establish a zebrafish model for studying arteriovenous malformations and related pathogenesis. Simetryn controls paddy weeds and can be used for research on developmental and vascular disorders.
-
APS-2-79 (Standard)
0 ImagesAPS-2-79 (Standard) is the analytical standard of APS-2-79 (HY-100627). This product is intended for research and analytical applications. APS-2-79 is a KSR-dependent MEK antagonist. APS-2-79 inhibits ATPbiotin binding to KSR2 within the KSR2-MEK1 complexe with an IC50 of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling.
-
Cefotetan (Standard)
0 ImagesCefotetan (Standard) is the analytical standard of Cefotetan. This product is intended for research and analytical applications. Cefotetan is a semisynthetic cephamycin antibiotic that exerts its bactericidal effects by inhibition of cell-wall synthesis.
-
N-Oxide Lidocaine-d10
0 ImagesCat. No.: HY-B0185SCAS No.: 851528-10-4N-Oxide Lidocaine-d10 is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.
-
Flurbiprofen axetil (Standard)
0 ImagesCat. No.: HY-101481RCAS No.: 91503-79-6Flurbiprofen axetil (Standard) is the analytical standard of Flurbiprofen axetil. This product is intended for research and analytical applications. Flurbiprofen axetil is a non-selective COX inhibitor and a nonsteroidal anti-inflammatory agent with anti-inflammatory and analgesic effects. Flurbiprofen axetil inhibits basal-like breast cancer metastasis by inhibiting the MEK/ERK signaling pathway. Flurbiprofen axetil can promote neuroprotection after focal cerebral ischemia in rats by partially activating PPAR-γ. Flurbiprofen axetil alleviates cerebral ischemia/reperfusion injury by reducing inflammation in a transient global cerebral ischemia/reperfusion rat model. Flurbiprofen axetil can alleviate inflammatory responses and cognitive function in a mild cognitive impairment (MCI) SD rat model through the AMPKα/NF-κB signaling pathway.
-
Binimetinib-d4
0 ImagesCat. No.: HY-15202S3CAS No.: 2890696-60-1Synonyms: MEK162-d4; ARRY-162-d4; ARRY-438162-d4Binimetinib-d4 (MEK162-d4) is deuterium labeled Binimetinib. Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC50 of 12 nM.
-
5-O-Methylvisammioside (Standard)
0 ImagesCat. No.: HY-N0442RCAS No.: 84272-85-5Synonyms: 4'-O-β-D-Glucosyl-5-O-methylvisamminol (Standard)5-O-Methylvisammioside (4'-O-β-D-Glucosyl-5-O-methylvisamminol) (Standard) is the analytical standard of 5-O-Methylvisammioside. This product is intended for research and analytical applications. 5-O-Methylvisammioside is an orally active natural chromone glycoside and multiple biological activities. 5-O-Methylvisammioside inhibits ferroptosis by activating the Nrf2/HO-1 signaling axis. 5-O-Methylvisammioside alleviates intestinal barrier damage by inhibiting the ROS/NF-κB/NLRP3 pathway. 5-O-Methylvisammioside exerts a protective effect against acute liver injury by reducing ALT/AST, decreasing inflammatory infiltration, and inhibiting IκB-α phosphorylation and NF-κB nuclear translocation. 5-O-Methylvisammioside blocks the HMGB1/RAGE/MEK/ERK signaling axis to exert anti-tumor and anti-angiogenic effects. 5-O-Methylvisammioside improves depression-like behaviors by inhibiting Src kinase and the NF-κB pathway.
-
Selumetinib sulfate (Standard)
0 ImagesSynonyms: AZD6244 sulfate (Standard); ARRY-142886 sulfate (Standard)Selumetinib (sulfate) (Standard) is the analytical standard of Selumetinib (sulfate). This product is intended for research and analytical applications. Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.
-
CI-1040 (Standard)
0 ImagesCat. No.: HY-50295RCAS No.: 212631-79-3Synonyms: PD 184352 (Standard)
-
PD-334581 (Standard)
0 ImagesCat. No.: HY-107619RCAS No.: 548756-68-9PD-334581 (Standard) is the analytical standard of PD-334581 (HY-107619). This product is intended for research and analytical applications. PD-334581 is a MEK1 inhibitor.
-
RO4987655 (Standard)
0 ImagesCat. No.: HY-14719RCAS No.: 874101-00-5Synonyms: CH4987655 (Standard)RO4987655 (Standard) is the analytical standard of RO4987655. This product is intended for research and analytical applications. RO4987655 is an orally active and highly selective MEK inhibitor with an IC50 of 5.2 nM for inhibition of MEK1/MEK2.
-
Mirdametinib (Standard)
0 ImagesSynonyms: PD0325901 (Standard); PD325901 (Standard)Mirdametinib (Standard) is the analytical standard of Mirdametinib (HY-10254). This product is intended for research and analytical applications. Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Kiapp of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts.
-
JTP-70902
0 ImagesCat. No.: HY-126048CAS No.: 871696-49-0JTP-70902, a p15INK4b-inductive compound, is a MEK1/2 inhibitor. JTP-70902 exhibits potent antitumor effect.
-
C16-PAF (Standard)
0 ImagesCat. No.: HY-108635RCAS No.: 74389-68-7Synonyms: PAF (C16) (Standard)C16-PAF (Standard) is the analytical standard of C16-PAF. This product is intended for research and analytical applications. C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability.
-
U0126 (Standard)
0 ImagesCat. No.: HY-12031ARCAS No.: 109511-58-2U0126 (Standard) is the analytical standard of U0126 (HY-12031A). This product is intended for research and analytical applications. U0126 is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC50s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor.
-
U0124 (Standard)
0 ImagesCat. No.: HY-107621RCAS No.: 108923-79-1U0124 (Standard) is the analytical standard of U0124 (HY-107621). This product is intended for research and analytical applications. U0124, an inactive U0126 analog, has no effect on c-Fos and c-Jun protein or mRNA levels. U0126 is a MEK inhibitor. U0124 does not inhibit MEK at concentrations up to 100 μM.
